Geriatric assessment of frailty in patients with Haematological Malignancies - A study determining the impact of frailty in older people with haematological malignancies.

Dr Angela Molga0 sites100 target enrollmentMarch 2, 2020

Overview

No summary available.

Registry

who.int

Start Date

March 2, 2020

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Sponsor

Dr Angela Molga

•Patients must satisfy the following criteria to be enrolled in the study:
•·Age 65 years or older
•·Diagnosis of haematological malignancy according to relevant classification system
•oLymphoma –diffuse B\-cell lymphoma (DLBCL)
•oMultiple myeloma – for first line treatment or first relapse
•oMyelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)
•·Ability to provide informed consent. If patients are from a non\-english speaking background, informed consent will be determined using an interpreter and including carers
•·Able to participate in study assessments
•·Life expectancy predicted by the clinician to be over 6 months
•·If therapy has commenced at the time of enrollment, then baseline assessments must be completed within 7 days of commencement of therapy

•·Age \<65 years of age
•·MDS, AML patients previously treated with azacitidine, intensive chemotherapy and/or allogeneic stem cell transplantation
•·DLBCL and multiple myeloma patients failed 2 lines of treatment
•·End of life care at time of enrollment
•·Best supportive care treatment at time of enrollment. Patients can be reconsented if they are then determined for active therapy and meet all other inclusion criteria.
•·Enrollment on any other study where non\-interventional studies are prohibited
•·Any significant condition that would confound the collection or interpretation of data from the study
•·Unable or unwilling to provide consent